Akrivia Biomedics Limited

At Akrivia, our vision is to help bring solutions to market that drive cancer treatment strategies from the current one-size-fits-all approach to the precision medicine approach in its truest sense. Cancer is a genetically heterogeneous disease, with a large number of genetic alterations present within a patient’s cancerous growth (typically, a single tumour contains anywhere from tens to millions of genomic aberrations). Founded by Amit Gupta, PhD, Akrivia is at heart an innovation maker with a focus on precision medicine in cancer treatment. Our founder has deep expertise in the field of translational cancer science and has been the lead in several significant research projects at multiple research institutes of repute, the Institute of Cancer Research, London, among them. We aim to be a force in tailored therapeutics where we are able to say more clearly to patients, payers, and providers – ‘this drug is not for everyone, but it is for you'. This is to be done based on a novel and innovative methodology developed by Akrvia’s founder, reflecting the intrinsic biology of the disease. Our innovative proprietary molecular sub-typing systems provide precise details on specific disease biology by considering each patient tumour's unique genomic and immune makeup. Our ultimate goal is to develop these innovative, ground-breaking classifier systems for clinical practice.